Text Size

Observational Study on Levemir® in Obese Diabetic Patients (KILOS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Novo Nordisk
ClinicalTrials.gov Identifier:
NCT00849342
First received: February 20, 2009
Last updated: January 30, 2013
Last verified: January 2013
History of Changes
  Purpose

This study is conducted in Europe. The aim of this observational study is to investigate the effect of switch from other basal insulin treatments to Levemir® on body weight in obese diabetic patients. A local extension will be conducted in Slovenia in order to reach the planned 400 patients for the sub-analysis of Slovenian patients.


Condition Intervention
Diabetes
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
 Drug: insulin detemir

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: A Prospective, Multicentre, Non-controlled, Observational, 52-weeks Study: the Evaluation of the Body Weight Progress During the Treatment With Insulin Detemir in Type 1 or 2 Diabetes Patients, Previously Treated With Other Basal Insulins

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Novo Nordisk:

Primary Outcome Measures:
  • Change in body weight and BMI [ Time Frame: during 12 months of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in body weight at different BMI subgroups [ Time Frame: at insulin start, 12 and 6 months before treatment and after 3, 6, 9 and 12 months of treatment ] [ Designated as safety issue: No ]
  • Change in waist perimeter [ Time Frame: from insulin start and after 6 and 12 months of treatment ] [ Designated as safety issue: No ]
  • Change in FPG (Fasting Plasma Glucose) [ Time Frame: from 12 and 6 months before treatment after 6 and 12 months of treatment ] [ Designated as safety issue: No ]
  • Change in HbA1C [ Time Frame: from insulin start and 12 and 6 months before treatment and after 6 and 12 months of treatment ] [ Designated as safety issue: No ]
  • Change in number of hypoglycaemic events during 4 weeks proceeding routine visits [ Time Frame: after 6 and 12 months of treatment ] [ Designated as safety issue: No ]
  • Number of adverse drug reactions (ADR) [ Time Frame: after 6 and 12 months of treatment ] [ Designated as safety issue: Yes ]
  • Change in blood pressure [ Time Frame: from insulin start and 6 and 12 months after treatment ] [ Designated as safety issue: No ]

Enrollment: 365
Study Start Date: January 2009
Study Completion Date: January 2013
Primary Completion Date: April 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
A Drug: insulin detemir
Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.

  Eligibility

Ages Eligible for Study:   6 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients from both general and speciality practice settings who have been deemed appropriate to receive Levemir® because of weight increase on other insulin therapies, and as part of routine out-patient care by the prescribing physician.

Criteria

Inclusion Criteria:

  • Diabetes mellitus (Type 1 or type 2)
  • BMI greater than 27 kg/m^2, or more than 3 kg weight increase since start of insulin therapy

Exclusion Criteria:

  • Subjects currently being treated with insulin detemir
  • Subjects who were previously enrolled in this study;
  • Subjects with a hypersensitivity to insulin detemir or to any of the excipients.
  • Women who are pregnant, breast feeding or have the intention of becoming pregnant within next 12 months Female patients will be reminded to use adequate contraceptive during the study, where is relevant.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00849342

Locations
Netherlands
Alphen a/d Rijn, Netherlands
Slovenia
Ljubljana, Slovenia, SI-1000
Sponsors and Collaborators
Novo Nordisk
Investigators
Study Director: Sarita Kesarlal, MSc Novo Nordisk B.V.
Study Director: Piet van der Wal, MD, PhD Novo Nordisk B.V.
  More Information

Additional Information:
Clinical Trials at Novo Nordisk  This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party: Novo Nordisk
ClinicalTrials.gov Identifier: NCT00849342     History of Changes
Other Study ID Numbers: NN304-3708
Study First Received: February 20, 2009
Last Updated: January 30, 2013
Health Authority: Netherlands: Medicines Evaluation Board, Dutch Health Care Inspectorate
Slovenia: Not required for observational study

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
 Immune System Diseases
Insulin
Insulin, Long-Acting
Hypoglycemic Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on May 23, 2013